Sage Therapeutics, Inc.

Sage Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing as a required component of its research and regulatory process. The company develops novel therapies for central nervous system disorders, a process that necessitates extensive non-clinical testing in animal models to assess pharmacology, toxicology, and potential efficacy before human trials can begin. This standard industry practice for drug development constitutes commercial exploitation of animals under the firm's exclusion policy.

While specific details on the scale and nature of Sage Therapeutics' animal testing are not publicly disclosed in its financial filings, the company's foundational research and regulatory submissions inherently involve animal subjects. Published preclinical studies for its drug candidates, such as zuranolone and SAGE-718, reference data derived from animal models. As a company without any marketed products generating revenue, its entire valuation is predicated on a research and development pipeline that is dependent on animal data to advance through clinical trials and secure regulatory approval from agencies like the U.S. Food and Drug Administration.